CoreCivic Reports Strong Q1 Results, Raises Full-Year Guidance, and Announces Strategic Acquisition

summarizeSummary

CoreCivic, Inc. announced robust first-quarter 2026 financial results, exceeding prior year performance, and raised its full-year guidance, while also revealing a strategic acquisition and continued share repurchases.

check_boxKey Events

• Strong Q1 2026 Financial Performance

  CoreCivic reported total revenue of $614.7 million, a 25.8% increase year-over-year, with net income up 51.0% to $37.9 million and diluted EPS rising 65.2% to $0.38. Adjusted EBITDA increased 36.0% to $110.1 million.

• Raised Full-Year 2026 Guidance

  The company updated its full-year 2026 guidance, increasing the low end of its Adjusted Diluted EPS range to $1.53-$1.63 (from $1.49-$1.59) and Adjusted EBITDA to $453.8 million-$461.8 million (from $437.0 million-$445.0 million), incorporating the CSP acquisition and facility activations.

• Strategic Acquisition of Clinical Solutions Pharmacy

  Subsequent to quarter-end, CoreCivic acquired Clinical Solutions Pharmacy (CSP) for approximately $148.0 million, expanding into mail order pharmacy services for correctional facilities and expecting to contribute $0.03 to $0.05 per share to 2026 earnings.

• Continued Share Repurchase Program

  During the first quarter of 2026, CoreCivic repurchased 2.3 million shares of common stock for $44.7 million, with $255.8 million remaining under the authorized $700.0 million program.

auto_awesomeAnalysis

CoreCivic, Inc. delivered a strong first quarter, with significant year-over-year growth across all key financial metrics, including revenue, net income, and EPS. The company also raised its full-year 2026 guidance, reflecting confidence in its operational performance despite a noted decrease in nationwide ICE populations. The strategic acquisition of Clinical Solutions Pharmacy for approximately $148 million is a material event, diversifying cash flows into a complementary and growing market, and is expected to contribute positively to EPS. Furthermore, the company's active share repurchase program continues to return capital to shareholders, with $44.7 million in repurchases during Q1. The $100 million incremental term loan enhances liquidity and balance sheet flexibility, supporting future growth initiatives. This filing paints a very positive picture of the company's financial health and strategic direction.